MIRA Current Deferred Revenue vs Net Tangible Assets Analysis

MIRA Stock

1.06 0.04 3.64%

MIRA Pharmaceuticals, financial indicator trend analysis is infinitely more than just investigating MIRA Pharmaceuticals, recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MIRA Pharmaceuticals, is a good investment. Please check the relationship between MIRA Pharmaceuticals, Current Deferred Revenue and its Net Tangible Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MIRA Pharmaceuticals, Current Deferred Revenue account and Net Tangible Assets. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between MIRA Pharmaceuticals,'s Current Deferred Revenue and Net Tangible Assets is -0.28. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of MIRA Pharmaceuticals, Common, assuming nothing else is changed. The correlation between historical values of MIRA Pharmaceuticals,'s Current Deferred Revenue and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of MIRA Pharmaceuticals, Common are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Current Deferred Revenue i.e., MIRA Pharmaceuticals,'s Current Deferred Revenue and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

-0.28

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from MIRA Pharmaceuticals,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MIRA Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

As of March 30, 2025, Selling General Administrative is expected to decline to about 3.3 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 6.1 M

	2022	2023	2024	2025 (projected)
Interest Expense	10.3K	3.5M	165.7K	157.4K
Depreciation And Amortization	7.0K	8.5M	9.8M	10.3M

Interest Expense Depreciation And Amortization

MIRA Pharmaceuticals, fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Other Current Assets	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Property Plant Equipment
Total Assets		-0.07	0.48	0.66	0.97	0.12	-0.98	-0.78	1.0	0.4	0.51	0.41	1.0	0.8	0.81	0.64	1.0	-0.08	-0.76	-0.73	0.42	-0.72	-0.71	0.59	-0.72	-0.42
Short Long Term Debt Total	-0.07		-0.3	0.61	-0.29	0.32	0.25	0.24	-0.15	0.85	0.46	0.4	-0.15	-0.38	-0.26	0.62	-0.14	0.99	0.55	0.65	0.12	-0.08	-0.09	-0.21	-0.08	0.33
Other Current Liab	0.48	-0.3		0.45	0.42	-0.28	-0.56	-0.86	0.49	-0.08	-0.04	-0.08	0.49	0.42	0.85	0.44	0.48	-0.34	-0.77	-0.72	-0.45	-0.68	-0.64	0.93	-0.67	-0.95
Total Current Liabilities	0.66	0.61	0.45		0.45	0.16	-0.55	-0.59	0.6	0.81	0.58	0.46	0.6	0.32	0.59	1.0	0.61	0.58	-0.31	-0.17	0.13	-0.73	-0.72	0.53	-0.73	-0.39
Total Stockholder Equity	0.97	-0.29	0.42	0.45		0.09	-0.98	-0.72	0.98	0.2	0.42	0.33	0.98	0.84	0.76	0.42	0.98	-0.29	-0.8	-0.81	0.45	-0.6	-0.6	0.52	-0.6	-0.37
Net Tangible Assets	0.12	0.32	-0.28	0.16	0.09		-0.04	0.38	0.09	0.59	0.88	0.94	0.09	-0.33	-0.33	0.15	0.08	0.42	0.41	0.28	-0.15	0.47	0.47	-0.37	0.47	0.27
Net Debt	-0.98	0.25	-0.56	-0.55	-0.98	-0.04		0.83	-0.99	-0.23	-0.4	-0.31	-0.99	-0.85	-0.86	-0.53	-0.99	0.26	0.85	0.83	-0.35	0.7	0.69	-0.63	0.7	0.52
Retained Earnings	-0.78	0.24	-0.86	-0.59	-0.72	0.38	0.83		-0.79	-0.05	-0.01	0.09	-0.79	-0.75	-1.0	-0.58	-0.79	0.29	0.93	0.84	-0.07	0.92	0.9	-0.93	0.91	0.79
Cash	1.0	-0.15	0.49	0.6	0.98	0.09	-0.99	-0.79		0.32	0.46	0.36	1.0	0.81	0.82	0.57	1.0	-0.16	-0.8	-0.78	0.41	-0.7	-0.7	0.6	-0.7	-0.42
Non Current Assets Total	0.4	0.85	-0.08	0.81	0.2	0.59	-0.23	-0.05	0.32		0.83	0.76	0.32	-0.07	0.06	0.81	0.33	0.87	0.22	0.28	0.19	-0.24	-0.25	0.0	-0.24	0.12
Non Currrent Assets Other	0.51	0.46	-0.04	0.58	0.42	0.88	-0.4	-0.01	0.46	0.83		0.99	0.46	0.0	0.06	0.56	0.46	0.53	0.1	0.04	0.07	0.01	0.01	-0.05	0.01	0.07
Other Assets	0.41	0.4	-0.08	0.46	0.33	0.94	-0.31	0.09	0.36	0.76	0.99		0.36	-0.11	-0.04	0.44	0.36	0.48	0.18	0.09	-0.04	0.15	0.15	-0.12	0.15	0.09
Cash And Short Term Investments	1.0	-0.15	0.49	0.6	0.98	0.09	-0.99	-0.79	1.0	0.32	0.46	0.36		0.81	0.82	0.57	1.0	-0.16	-0.8	-0.78	0.41	-0.7	-0.7	0.6	-0.7	-0.42
Common Stock Shares Outstanding	0.8	-0.38	0.42	0.32	0.84	-0.33	-0.85	-0.75	0.81	-0.07	0.0	-0.11	0.81		0.79	0.31	0.82	-0.42	-0.86	-0.75	0.54	-0.71	-0.67	0.47	-0.71	-0.48
Other Stockholder Equity	0.81	-0.26	0.85	0.59	0.76	-0.33	-0.86	-1.0	0.82	0.06	0.06	-0.04	0.82	0.79		0.58	0.82	-0.31	-0.94	-0.85	0.09	-0.9	-0.88	0.9	-0.9	-0.8
Total Liab	0.64	0.62	0.44	1.0	0.42	0.15	-0.53	-0.58	0.57	0.81	0.56	0.44	0.57	0.31	0.58		0.59	0.59	-0.29	-0.15	0.13	-0.73	-0.72	0.52	-0.73	-0.38
Total Current Assets	1.0	-0.14	0.48	0.61	0.98	0.08	-0.99	-0.79	1.0	0.33	0.46	0.36	1.0	0.82	0.82	0.59		-0.15	-0.79	-0.77	0.43	-0.71	-0.71	0.6	-0.71	-0.42
Short Term Debt	-0.08	0.99	-0.34	0.58	-0.29	0.42	0.26	0.29	-0.16	0.87	0.53	0.48	-0.16	-0.42	-0.31	0.59	-0.15		0.59	0.68	0.1	0.0	-0.02	-0.26	0.0	0.36
Common Stock	-0.76	0.55	-0.77	-0.31	-0.8	0.41	0.85	0.93	-0.8	0.22	0.1	0.18	-0.8	-0.86	-0.94	-0.29	-0.79	0.59		0.96	-0.15	0.77	0.75	-0.81	0.76	0.73
Accounts Payable	-0.73	0.65	-0.72	-0.17	-0.81	0.28	0.83	0.84	-0.78	0.28	0.04	0.09	-0.78	-0.75	-0.85	-0.15	-0.77	0.68	0.96		-0.08	0.61	0.61	-0.78	0.6	0.63
Other Current Assets	0.42	0.12	-0.45	0.13	0.45	-0.15	-0.35	-0.07	0.41	0.19	0.07	-0.04	0.41	0.54	0.09	0.13	0.43	0.1	-0.15	-0.08		-0.27	-0.3	-0.21	-0.29	0.44
Net Invested Capital	-0.72	-0.08	-0.68	-0.73	-0.6	0.47	0.7	0.92	-0.7	-0.24	0.01	0.15	-0.7	-0.71	-0.9	-0.73	-0.71	0.0	0.77	0.61	-0.27		0.99	-0.82	1.0	0.61
Short Long Term Debt	-0.71	-0.09	-0.64	-0.72	-0.6	0.47	0.69	0.9	-0.7	-0.25	0.01	0.15	-0.7	-0.67	-0.88	-0.72	-0.71	-0.02	0.75	0.61	-0.3	0.99		-0.83	0.99	0.53
Capital Stock	0.59	-0.21	0.93	0.53	0.52	-0.37	-0.63	-0.93	0.6	0.0	-0.05	-0.12	0.6	0.47	0.9	0.52	0.6	-0.26	-0.81	-0.78	-0.21	-0.82	-0.83		-0.81	-0.79
Net Working Capital	-0.72	-0.08	-0.67	-0.73	-0.6	0.47	0.7	0.91	-0.7	-0.24	0.01	0.15	-0.7	-0.71	-0.9	-0.73	-0.71	0.0	0.76	0.6	-0.29	1.0	0.99	-0.81		0.6
Property Plant Equipment	-0.42	0.33	-0.95	-0.39	-0.37	0.27	0.52	0.79	-0.42	0.12	0.07	0.09	-0.42	-0.48	-0.8	-0.38	-0.42	0.36	0.73	0.63	0.44	0.61	0.53	-0.79	0.6

Click cells to compare fundamentals

MIRA Pharmaceuticals, Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether MIRA Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MIRA Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mira Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mira Pharmaceuticals, Common Stock:

How To Invest In MIRA

Details

Is MIRA Stock a good investment?

Details

What is MIRA Pharmaceuticals,'s Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MIRA Pharmaceuticals, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MIRA Pharmaceuticals,. If investors know MIRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MIRA Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.55)

Return On Assets

(0.81)

Return On Equity

(1.92)

The market value of MIRA Pharmaceuticals, is measured differently than its book value, which is the value of MIRA that is recorded on the company's balance sheet. Investors also form their own opinion of MIRA Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is MIRA Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MIRA Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect MIRA Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MIRA Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if MIRA Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MIRA Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MIRA Current Deferred Revenue vs Net Tangible Assets Analysis

Current Deferred Revenue vs Net Tangible Assets

Current Deferred Revenue vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Net Tangible Assets

MIRA Pharmaceuticals, fundamental ratios Correlations

MIRA Pharmaceuticals, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Other Stockholder Equity	- 1.0	Retained Earnings
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets